Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | CDK14 | O94921 | 1/20 | 0.38 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909617 | 0.91 | JAK3 (0.41) | BTKJAK3CDK7CDK9 | |
| SCHEMBL19054740 | 0.87 | BTK (0.39) | BTKJAK3CDK14CCNYHDAC1 | |
| SCHEMBL18909558 | 0.85 | JAK3 (0.41) | BTKJAK3 | |
| SCHEMBL20839791 | 0.84 | ITGB3 (0.40) | BTKJAK3CDK14CCNYHDAC1 | |
| SCHEMBL20839793 | 0.84 | ITGB3 (0.40) | BTKJAK3CDK14CCNYHDAC1 | |
| SCHEMBL18331788 | 0.84 | JAK3 (0.46) | BTKJAK3 | |
| SCHEMBL18431345 | 0.84 | JAK3 (0.46) | BTKJAK3 | |
| SCHEMBL18909691 | 0.84 | JAK3 (0.46) | BTKJAK3 | |
| SCHEMBL17244275 | 0.83 | HDAC1 (0.41) | BTKJAK3CDK14CCNYHDAC1 | |
| SCHEMBL462207 | 0.83 | ALDH1A1 (0.44) | BTKJAK3CDK14CCNYHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3707133-B1 | BTK INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2021-12-15 | — | — | EP | disclosed |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200276199-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2020-09-03 | — | — | US | disclosed |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | BTK 329/4885JAK3 192/4885CDK14 126/4885 |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | BTK 66/4885JAK3 447/4885CDK14 234/4885 |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | IRAK1, IRAK4, IRAK2 | BTK 329/4885JAK3 192/4885CDK14 126/4885 |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | BTK 329/4885JAK3 192/4885CDK14 126/4885 |
| US-20200276199-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | BTK 1/4885JAK3 45/4885CDK14 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.